The U.S. September Consumer Price Index (CPI) report has rattled financial markets, as "sticky" core inflation pressures raise the possibility of an earlier-than-expected interest rate hike by the Federal Reserve.
South Korean biotech firm Mezzion Pharma is expanding its pivotal Phase 3 trial for Udenafil to Europe as it moves toward a potential 2027 FDA filing, with peak annual U.S. sales estimated at $3 billion.
HLB Therapeutics CEO An Ki-hong emphasized that the superior convenience and safety profile of RGN-259 will drive its adoption as a primary treatment for neurotrophic keratitis (NK), with top-line results from the SEER-2 global Phase 3 clinical trial expected by mid-November.
HLB Therapeutics is preparing for a make-or-break moment in November, as it awaits the top-line results of its U.S. Phase 3 "SEER-2" trial for the neurotrophic keratitis (NK) treatment candidate RGN-259. The company aims to challenge the U.S. market dominance of Dompé’s "Oxervate," leveraging the logistical advantages of a shelf-stable, short-term treatment regimen.
![[K-Bio Global Phase 3] Fred Kim, Head of AriBio US: "AR1001 Aims to Become the First-Line Therapy for Early Alzheimer’s"](https://media.markettimes.co.kr/20261001_105713-1-400x300.webp)
AriBio’s U.S. division head, Fred Kim, outlined the company’s ambition to position its oral Alzheimer’s candidate, AR1001, as a first-line treatment, with global Phase 3 trial results set for release in November 2026.
ArisBio is gearing up for the pivotal November release of its Phase 3 global clinical trial results for its oral Alzheimer's treatment candidate, AR1001, setting its sights on U.S. FDA approval by 2028 and a 1 trillion won revenue milestone by 2030.
While the KOSPI finished September in positive territory, the broader market suffered a severe breadth contraction as heavyweights Samsung Electronics and SK hynix propped up the index while nearly 70% of listed issues declined.
Behind Micron’s robust quarterly earnings lies an even stronger industry signal, as hyperscalers and AI data centers rush to lock in memory supply agreements stretching all the way to 2031.
Global technology giants are moving beyond conversational chatbots to always-on autonomous AI agents capable of executing tasks, scheduling, and data analysis in the background without user intervention.
HanAll Biopharma’s autoimmune disease treatment batoclimab has received marketing approval in China following successful Phase 3 clinical trials, paving the way for milestone payments and sales royalties. Meanwhile, its next-generation candidate, imireprovat (IMVT-1402), is undergoing global Phase 3 trials for generalized myasthenia gravis, with early therapeutic responses also observed in rheumatoid arthritis.
